KR101721145B1 - - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement - Google Patents
- Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement Download PDFInfo
- Publication number
- KR101721145B1 KR101721145B1 KR1020150107087A KR20150107087A KR101721145B1 KR 101721145 B1 KR101721145 B1 KR 101721145B1 KR 1020150107087 A KR1020150107087 A KR 1020150107087A KR 20150107087 A KR20150107087 A KR 20150107087A KR 101721145 B1 KR101721145 B1 KR 101721145B1
- Authority
- KR
- South Korea
- Prior art keywords
- carnitine
- magnesium
- magnesium citrate
- food composition
- citrate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 235000013305 food Nutrition 0.000 title claims abstract description 32
- 235000005911 diet Nutrition 0.000 title claims abstract description 29
- 239000004337 magnesium citrate Substances 0.000 title claims description 8
- 229960005336 magnesium citrate Drugs 0.000 title claims description 8
- 235000002538 magnesium citrate Nutrition 0.000 title claims description 8
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 title claims description 8
- 230000037213 diet Effects 0.000 title abstract description 18
- 230000001737 promoting effect Effects 0.000 title abstract description 16
- 229960004203 carnitine Drugs 0.000 title description 4
- VIOYPGDQEDDCJB-UUCJDPIKSA-H trimagnesium;2-hydroxypropane-1,2,3-tricarboxylate;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound [Mg+2].[Mg+2].[Mg+2].C[N+](C)(C)C[C@H](O)CC([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VIOYPGDQEDDCJB-UUCJDPIKSA-H 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 235000001916 dieting Nutrition 0.000 claims abstract description 6
- 230000037228 dieting effect Effects 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 47
- 239000000843 powder Substances 0.000 claims description 31
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 22
- 239000011777 magnesium Substances 0.000 claims description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 241000723343 Cichorium Species 0.000 claims description 12
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 12
- 230000000378 dietary effect Effects 0.000 claims description 11
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- 150000003839 salts Chemical group 0.000 claims description 8
- 235000005979 Citrus limon Nutrition 0.000 claims description 7
- 244000131522 Citrus pyriformis Species 0.000 claims description 7
- 229920000084 Gum arabic Polymers 0.000 claims description 7
- 239000000205 acacia gum Substances 0.000 claims description 7
- 235000010489 acacia gum Nutrition 0.000 claims description 7
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 230000000638 stimulation Effects 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 229930003471 Vitamin B2 Natural products 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229960002477 riboflavin Drugs 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- 235000019164 vitamin B2 Nutrition 0.000 claims description 4
- 239000011716 vitamin B2 Substances 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- DEVLFMFUNRCKGE-FYZOBXCZSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O DEVLFMFUNRCKGE-FYZOBXCZSA-N 0.000 claims description 2
- 150000004684 trihydrates Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 230000004580 weight loss Effects 0.000 abstract description 15
- 230000004936 stimulating effect Effects 0.000 abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 19
- 229910052749 magnesium Inorganic materials 0.000 description 19
- 229940091250 magnesium supplement Drugs 0.000 description 19
- 230000006870 function Effects 0.000 description 14
- 229960004106 citric acid Drugs 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000013872 defecation Effects 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 241000208140 Acer Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 4
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- AUSHDAODAXKKDJ-FYZOBXCZSA-N (3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate;magnesium Chemical compound [Mg].C[N+](C)(C)C[C@H](O)CC([O-])=O AUSHDAODAXKKDJ-FYZOBXCZSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229960003390 magnesium sulfate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008147 saline laxative Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 description 1
- CQMNNMLVXSWLCH-UHFFFAOYSA-B 2-hydroxypropane-1,2,3-tricarboxylate;tin(4+) Chemical compound [Sn+4].[Sn+4].[Sn+4].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O CQMNNMLVXSWLCH-UHFFFAOYSA-B 0.000 description 1
- ROYPGAQNKYWYDI-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;magnesium Chemical compound [Mg].OC(=O)CC(O)(C(O)=O)CC(O)=O ROYPGAQNKYWYDI-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HNSUOMBUJRUZHJ-REVJHSINSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-REVJHSINSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- AYAHVULUMILDAD-FYZOBXCZSA-N hexanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)CCCCC(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O AYAHVULUMILDAD-FYZOBXCZSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- -1 jatritol Chemical compound 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 238000009140 magnesium supplementation Methods 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/161—Magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7042—Vitamin B1
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7044—Vitamin B2
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a food composition for facilitating bowel movement including magnesium L-carnitine citrate, and its object is to provide a food composition for promoting bowel movement including magnesium L-carnitine citrate which can give a dieting function while increasing bowel activity To provide a food composition.
INDUSTRIAL APPLICABILITY The food composition for stimulating or stimulating bowel movement according to the present invention is provided with a function of promoting bowel movement and a diet (weight loss) using L-Carnitine Magnesium Citrate as an active ingredient.
Description
The present invention relates to a food composition for promoting bowel movement including magnesium L-carnitine citrate, and a composition for promoting bowel movement including dietary magnesium-citrate, which is capable of imparting a dieting function while increasing bowel activity .
In recent years, modern society has been experiencing a lot of changes in living habits due to the improvement of living standards due to the high economic growth, and the increase of the obesity population due to the change from the fiber-centered diet to the meat- It is progressing.
In particular, the consumption of foods using instant foods and refined raw materials is increasing, while the static working environment in the office and the decrease in the individual's mobility have caused modern people to suffer from early mild symptoms such as constipation and obesity, Hyperlipidemia, and diabetes mellitus. Among them, the increase in abdominal obesity, which is a major cause of various adult diseases, is remarkable.
As a method for treating and preventing such obesity, improvement of eating habits, maintenance of proper exercise, control of caloric intake, etc. have been used. However, improvement of the dietary life requires expert knowledge, So that it is not easy for busy modern people to easily apply and practice.
Recently, there has been much interest in control of calorie intake using diet foods, and various diet-related products are being released in line with the trends of such consumers.
However, the conventional diet-related products are Saline Laxatives (Osmotic Laxatives), which act as an osmotic active ingredient in saliva and prevent moisture absorption from the barrier to maintain the moisture content of the side, Magnesium sulfate, magnesium hydroxide, magnesium citrate, magnesium phosphate tribasic, magnesium oxide, magnesium chloride, and the like are used. However, , And such a salt-type emollient has disadvantages that it does not dissolve well in a liquid form preparation or tastes poor in taste.
In addition, conventional defecation-promoting and diet-related products can not say that the effect is necessarily sufficient, there is a possibility of improvement because there is no immediate effect, and in the case of a food supplement using a chemical compound, .
In addition, some conventional diet food compositions use expensive natural raw materials and herbal medicines. However, the conventional dietary food compositions have problems such as poor preservability and insufficient effects of defecation activity and weight loss, Not too many.
Thus, there has been an increasing need for diet products that are effective in suppressing obesity and weight loss due to an increase in interest in appearance and health, regardless of whether they are young or old, .
It is an object of the present invention to provide a food composition for accelerating bowel movement or diet food containing magnesium L-carnitine citrate capable of imparting a dieting function while increasing bowel activity.
INDUSTRIAL APPLICABILITY The food composition for stimulating or stimulating bowel movement according to the present invention is provided with a function of promoting bowel movement and a diet (weight loss) using L-Carnitine Magnesium Citrate as an active ingredient.
Here, 0.1 to 60 wt% of L-Carnitine Magnesium Citrate can be contained as an active ingredient.
In addition, 0.1 to 30 wt% of L-Carnitine Magnesium Citrate may be contained as an active ingredient.
The L-carnitine magnesium citrate may be integrated with a magnesium citrate mixture in L-carnitine in a complex salt form.
The L-carnitine magnesium citrate is prepared by mixing 120 to 140 parts by weight of anhydrous citric acid and 35 to 42 parts by weight of Mg (OH) 2 in a mill for 5 to 7 minutes, mixing 30 to 40 parts by weight of deionized water, 100 parts by weight of L-carnitine was added thereto and kneaded for 40 to 50 minutes at a rate of 40 to 50 revolutions / minute, followed by maintaining at 90 占 폚 in a vacuum It can be dried for 200 to 240 minutes.
In addition, the food composition for dietary promotion combined with a bowel movement comprises 0.1 to 60 wt% of L-carnitine magnesium citrate, 1 to 15 wt% of fructooligosaccharide, 1 to 12 wt% of xylitol, 1 to 12 wt% of sorbitol, 0.1 to 1.0 wt.% Of chicory extract powder, 0.1 to 1.0 wt.% Of acacia gum, 0.1 to 1.5 wt.% Of phosphoric acid, 0.01 to 0.15 wt.% Of trihydrate powder, 0.01 to 0.2 wt. , Anhydrous citric acid 0.1 to 1.5 wt%, and purified water 35 to 65 wt%. At this time, the food composition for dietary stimulation combined with urine may further contain 0.005 to 0.02% by weight of vitamin B2 and 0.005 to 0.02% by weight of vitamin B1 hydrochloride.
In addition, the food composition for dietary stimulation combined with a bowel movement comprises 1 to 30 wt% of L-carnitine magnesium citrate, 8 to 13 wt% of fructooligosaccharide, 8 to 12 wt% of xylitol, 8 to 12 wt% of sorbitol, 0.5 to 1.5 wt% 0.3 to 0.7 wt.% Of chicory extract powder, 0.3 to 0.7 wt.% Of acacia gum, 0.7 to 1.5 wt.% Of phosphoric acid, 0.05 to 0.15 wt.% Of phosphoric acid powder, 0.05 to 0.1 wt. , Anhydrous citric acid 0.5 to 1.5 wt%, and purified water 40 to 65 wt%.
In addition, the food composition for dietary stimulation combined with the urine can be produced in the form of powder, liquid, tablet, granule, capsule, soft capsule.
The present invention includes L-carnitine magnesium citrate, and has a body weight reducing effect due to accelerated bowel movement and body fat decomposition.
The L-carnitine magnesium citrate according to the present invention is composed of magnesium, which has an excellent effect on defecation activity and is made of a material mixed with L-carnitine in a mixed salt form together with citric acid, so that the bitterness In addition, there is an effect of accelerating the supplementation of magnesium in terms of bioavailability and absorption.
INDUSTRIAL APPLICABILITY The present invention is excellent in the absorption rate of magnesium, and induces active secretion of water into the intestinal tract by the action of magnesium smoothly, resulting in effective defecation.
The present invention can be combined with various additives such as dietary fiber, saccharides and the like to promote the stimulation of bowel movement and improve the diet promoting effect.
The present invention relates to a composition for promoting excellent bowel movement and promoting diet when mixed with fructooligosaccharide, jatritol, sorbitol, lemon juice powder, tin citrate, maple syrup powder, chicory extract powder, acacia gum, phosphoric acid, Respectively.
The food composition for dietary promotion combined with L-Carnitine Magnesium Citrate according to the present invention may be in various forms such as powder, liquid, tablet, granule, capsule, and soft capsule Which can be easily taken by anyone, and so on.
Fig. 1 is an exemplary diagram showing the results of Example 2 of the present invention. Fig.
FIG. 2 is a view showing an example of a weight loss comparison chart according to
The present invention uses L-Carnitine Magnesium Citrate as an active ingredient and has a function of promoting bowel movement and a diet (weight loss) function.
The present invention is characterized by containing 0.1 to 60 wt% of L-Carnitine Magnesium Citrate as an active ingredient, preferably 1 to 30 wt%, more preferably 1 to 20 wt% .
The L-carnitine magnesium citrate is a solid form of a magnesium citrate mixture in L-carnitine. The magnesium-citric acid mixture has an effect of facilitating bowel movement, reducing body fat, promoting metabolism of body energy and reducing body weight have. That is, the L-carnitine magnesium citrate has a function of magnesium citrate present in a mixed salt form and an excellent fat reducing or reducing effect by the function of L-carnitine.
In addition, the L-carnitine magnesium citrate itself has a function of directly participating in energy metabolism so as to restore fatigue or provide vitality to the body, and has an ascending function of being able to be absorbed by iron by binding with iron, And has excellent storage stability and uniform distribution.
The L-carnitine magnesium citrate will be described in more detail as follows.
L-Carnitine is an endogenous substance biosynthesized from lysine and methionine in vivo, and has the property of generating energy by transporting fatty acids from the cytoplasm to mitochondria.
However, when L-carnitine is exposed to a humid environment, it absorbs the surrounding water and exhibits deliquescence that becomes a dissolved state. This characteristic is attributed to the fact that in the solid preparation containing the L-carnitine, Thereby adversely affecting the stability of the battery.
For this reason, in recent years, a number of non-hygroscopic salts of L-carnitine have been developed which have low absorption properties such as L-carnitine tartrate, L-carnitine fumarate, L-carnitine adipate and L- However, when they are not packaged to completely block the moisture, there is a serious problem that the product is deformed because the salt of L-carnitine is disturbed over time during storage.
However, the L-carnitine magnesium citrate according to the present invention has a low absorbency at a relative humidity (rH) of 56% which is only about 8% by weight more than the initial value even after about 15 days.
In addition, the non-hygroscopic salts of L-carnitine have a characteristic odor after storage for a certain period of time, causing discomfort to the user when used as food for diet. However, L-carnitine magnesium citrate The same phenomenon does not occur.
In addition, since L-carnitine magnesium citrate according to the present invention is composed of one substance having excellent effect on defecation activity and mixed with L-carnitine in a mixed salt form together with citric acid, the magnesium has a bitter taste In addition to being removed, magnesium supplementation is quick and excellent in terms of bioavailability and absorption.
For example, when about 100 mg of magnesium is taken by magnesium L-carnitine citrate according to the present invention, the human body of the recipient almost absorbs about 15 to 20 mg of magnesium. Considering that the absorption of magnesium is only 8 to 12 mg when magnesium is used in the same amount of sulfate or chloride that is widely used to take magnesium, .
That is, it can be seen that magnesium L-carnitine according to the present invention exerts the same effect or more than the conventional magnesium-containing sulfate or chloride form even when a small amount of magnesium is consumed.
In addition, L-carnitine has a function of regulating lipid oxidation, which is a process of energy metabolism of fat cells by Carnitine Palmitoyl Transferase (CPT), but its activity is inhibited by malonyl CoA.
However, L-carnitine magnesium citrate according to the present invention inhibits the synthesis of malonyl-CoA by citric acid contained therein, and the activity of L-carnitine is assisted by magnesium, thereby activating the carnitine palmitoyl transferase (CPT) .
Carnitine, citric acid and magnesium are not expected to be expected when L-carnitine, citric acid or magnesium is contained as a single substance. This is an effect expected only by a single substance of magnesium L-carnitine citrate as in the present invention, - Carnitine enzyme system is a synergistic effect that occurs as a result of simultaneous control by magnesium ion and citric acid.
The above-mentioned L-carnitine magnesium citrate is not particularly limited, but for example, 120-140 parts by weight of anhydrous citric acid and 35-42 parts by weight of Mg (OH) 2 are mixed in the wheat for about 5-7 minutes , 30 to 40 parts by weight of deionized water, and the mixture is heated to about 75 DEG C to 80 DEG C for about 20 to 40 minutes, 100 parts by weight of L-carnitine is added, and the mixture is stirred for 40 to 50 minutes / Min, followed by drying for about 200 to 240 minutes while maintaining about 90 캜 in a vacuum.
In addition, the formulations containing L-carnitine magnesium citrate may be in the form of powders, liquids, tablets, granules, capsules, soft capsules.
Hereinafter, components to be added to the composition for promoting bowel movement or diet food containing magnesium L-carnitine citrate as an active ingredient according to the present invention will be specifically described.
The present invention relates to a pharmaceutical composition comprising 0.1 to 60 wt% of L-carnitine magnesium citrate, 1 to 15 wt% of fructooligosaccharide (100%), 1 to 12 wt% of xylitol, 1 to 12 wt% of sorbitol, 0.1 to 1.5 wt% of lemon juice powder, 0.1 to 0.7 wt% of maple syrup powder, 0.1 to 1.0 wt% of chicory extract powder, 0.1 to 1.0 wt% of acacia gum, 0.1 to 1.5 wt% of phosphoric acid, 0.01 to 0.15 wt% of triple- To 1.5 wt%, and purified water 35 to 65 wt%.
The present invention also relates to a pharmaceutical composition comprising 1 to 30 wt% of L-carnitine citrate, 8 to 13 wt% of fructooligosaccharide (100%), 8 to 12 wt% of xylitol, 8 to 12 wt% of sorbitol, 0.5 to 1.5 wt% 0.05 to 0.15 wt% of ginseng sodium, 0.3 to 0.7 wt% of maple syrup powder, 0.3 to 0.7 wt% of chicory extract powder, 0.3 to 0.7 wt% of acacia gum, 0.7 to 1.5 wt% of phosphoric acid, Citric acid 0.5-1.5 wt%, and purified water 40-65 wt%.
The present invention further includes 0.005 to 0.02 wt% of vitamin B2 (33.3%) and 0.005 to 0.02 wt% of vitamin B1 hydrochloride.
The fructooligosaccharide, like isomaltooligosaccharide, selectively proliferates bifidobacteria which is a type of intestinal lactic acid bacteria, thereby inhibiting the production of perishable products in the intestines, and improving bowel function, thereby preventing obesity and promoting bowel movement do.
The fructooligosaccharide is an oligosaccharide made by enzymatically decomposing sugar as a raw material and has a very low calorie characteristic. For example, the fructooligosaccharide has a fructooligosaccharide content of 239 kcal and the isomaltooligosaccharide has a fructose content of 280 kcal based on 100 g.
In addition, the fructooligosaccharide has a high content of dietary fiber, so that the dietary fiber rich in the fructooligosaccharide helps the intestinal health. In other words, it has a good bifidus growth effect on the body, so it suppresses intestinal decay and cleanses the intestinal environment, thereby promoting bowel movement.
The xylitol and sorbitol liquids are sugar components and together with fructooligosaccharides have the function of enhancing the sweetness of the food composition of the present invention. At this time, the components are sweet, but have little or no calories, . The sound bitol has higher calorie and less sweetness than xylitol, so it is preferable to contain xylitol more than sorbitol.
The lemon juice powders dissolve succulents of the large intestine by releasing sour taste of limonene, citric acid, and lemon acid and dissolve wastes such as thrombus by acting on blood vessels of important organs of the body, And has effects of body detoxification and weight loss.
In addition, the lemon juice powder is rich in citric acid and vitamin C, and has an excellent effect on skin beauty.
Since the chicory extract powder is the dietary fiber itself like the indigestible maltodextrin, it has an effect of suppressing the formation of satiety and suppressing the lipid absorption in the intestines. The roots of the chicory contain a large amount of stored carbohydrates, which are composed of fructooligosaccharides having a sugar content of 20 or less and inulin having a size of 20 or more. These components are water-soluble and are hardly hydrolyzed by the digestive enzymes in vivo, and are used by intestinal bacteria.
It is also known that the chicory extract powder has a preventive and therapeutic effect on chronic degenerative diseases such as hyperlipidemia and diabetes.
When the chicory extract powder is contained in an amount less than 0.1% by weight, it is difficult to expect a satisfactory filling feeling and lipid absorption inhibiting effect. When the chicory extract powder is contained in an amount exceeding 1.0% by weight, Lt; / RTI >
The maple syrup powder is a low-calorie food rich in potassium, calcium and magnesium, and has the effect of slowing the growth of cancer cells and containing plant hormone called ascorbic acid to promote insulin secretion, thereby reducing the risk of diabetes.
The acacia black beans are prepared by mechanically squeezing, drying or desalting a gum of Arabian rubber trees or other plants of the same species, containing at least 80% of dietary fiber and having a function of smoothly discharging.
The trifoliate powder has a function of suppressing the synthesis of cholesterol and having a thrombolytic action and an obesity-suppressing action, and contains cellulose in its inside, cleansing blood, promoting bowel movement and reducing body weight. In addition, the above-mentioned triple-leaf powder contains a sulfur component which is five times as much as garlic, thereby preventing aging of the skin and also excelling in anticancer action.
The anhydrous citric acid is added as a pH adjusting agent, but it prevents unnecessary accumulation of lactic acid and has a function of decomposing body fat, and has an excellent effect on skin beauty and diet.
In the present invention, trisodium citrate was used as a pH adjusting agent, and phosphoric acid was used as a material for sweetening the liquid formulation. Since the above-mentioned sodium citrate and phosphoric acid are widely used as food additives, a detailed description thereof will be omitted.
In addition to the above components, the present invention may further include food-acceptable natural or synthetic additives, various vitamins, various nutrients, natural or synthetic flavors, stabilizers and the like.
Hereinafter, the present invention will be described in detail with reference to the following examples.
≪ Example 1 >
L-Carnitine Magnesium citrate was added to purified water to evaluate its solubility and taste in the dissolved state. The results are shown in Table 1.
The evaluation of palatability was carried out 5 times over 5 days, 10 times in 20 women, 10 women in their 30s and 10 women in their 40s who were interested in diet foods. .
[Table 1]
As shown in Table 1, magnesium L-carnitine citrate according to the present invention is excellent in solubility in water and has excellent palatability as compared with when a component used as saline laxatives (Osmotic Laxatives) is added As shown in FIG.
This is because the magnesium sulfate or magnesium chloride form does not dissolve well in the liquid formulation or the taste characteristic of magnesium is left, and the taste of the magnesium is inferior to the taste. However, the magnesium L-carnitine according to the present invention, Carnitine is mixed with citric acid in combination with citric acid, so it is considered to be an effect that the bitterness of magnesium is displeased due to unpleasantness.
≪ Example 2 >
[Table 2]
[Table 3]
As can be seen from [Table 3] and FIG. 1, it can be seen that the present invention has a defecation success rate of 55% or more, and in particular, in the case of the
≪ Example 3 >
Using
At this time, L-carnitine magnesium citrate was not added as a contrast group and purified water was further added, and other components were blended so as to be the same as
FIG. 2 shows an example of weight loss comparison chart according to Example 3. In the control group, six out of 10 patients showed only normal weight change, while the remaining four showed no change or weight gain.
In contrast, 2 of 10 people who lost 1 to 2 kg of weight loss when ingesting magnesium L-carnitine citrate, 6 of those who lost 2 to 3 kg of weight loss, 1 person, 4 ~ 5 ㎏ showed weight loss, and 10 people showed weight loss.
In addition, the average weight loss for the tester was about 2.57 kg, which indicates that the food composition of the present invention is effective for weight loss and for bowel activity.
It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined in the appended claims and their equivalents. Of course, such modifications are within the scope of the claims.
Claims (10)
The L-carnitine magnesium citrate is prepared by mixing 120 to 140 parts by weight of anhydrous citric acid and 35 to 42 parts by weight of Mg (OH) 2 in a mill for 5 to 7 minutes, mixing 30 to 40 parts by weight of deionized water, 100 parts by weight of L-carnitine was added thereto and kneaded for 40 to 50 minutes at a rate of 40 to 50 revolutions / minute, followed by maintaining at 90 占 폚 in a vacuum Wherein the composition is dried for 200 to 240 minutes.
A food composition for dieting promotion combined with diabetes, which comprises 0.1 to 60 wt% of L-Carnitine Magnesium Citrate as an active ingredient.
A food composition for dieting promotion combined with food, which comprises 0.1 to 30 wt% of L-Carnitine Magnesium Citrate as an active ingredient.
L-carnitine is a combination of magnesium citrate and L-carnitine in a complex salt form.
A food composition for dietary promotion,
L-carnitine 0.1 to 60 wt% of magnesium citrate, 1 to 15 wt% of fructooligosaccharide, 1 to 12 wt% of xylitol, 1 to 12 wt% of sorbitol, 0.1 to 1.5 wt% of lemon juice powder, 0.01 to 0.2 wt% 0.1 to 1.0 wt% of chicory extract powder, 0.1 to 1.0 wt% of acacia gum, 0.1 to 1.5 wt% of phosphoric acid, 0.01 to 0.15 wt% of trihydrate powder, 0.1 to 1.5 wt% of anhydrous citric acid, To 65 wt% based on the total weight of the composition.
0.005 to 0.02 wt% of vitamin B2, and 0.005 to 0.02 wt% of vitamin B1 hydrochloride.
A food composition for dietary promotion,
1 to 30 wt% of L-carnitine citrate, 8 to 13 wt% of fructooligosaccharide, 8 to 12 wt% of xylitol, 8 to 12 wt% of sorbitol, 0.5 to 1.5 wt% of lemon juice powder, 0.05 to 0.15 wt% 0.3 to 0.7 wt% of syrup powder, 0.3 to 0.7 wt% of chicory extract powder, 0.3 to 0.7 wt% of acacia gum, 0.7 to 1.5 wt% of phosphoric acid, 0.05 to 0.15 wt% of triple- To 65 wt% based on the total weight of the composition.
0.005 to 0.02 wt% of vitamin B2, and 0.005 to 0.02 wt% of vitamin B1 hydrochloride.
Wherein the food composition for dieting promotion combined with dietary stimulation is prepared in the form of one of powder, liquid, tablet, granule, capsule, and soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150107087A KR101721145B1 (en) | 2015-07-29 | 2015-07-29 | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150107087A KR101721145B1 (en) | 2015-07-29 | 2015-07-29 | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170014179A KR20170014179A (en) | 2017-02-08 |
| KR101721145B1 true KR101721145B1 (en) | 2017-03-29 |
Family
ID=58154737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150107087A KR101721145B1 (en) | 2015-07-29 | 2015-07-29 | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101721145B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210104952A (en) | 2020-02-17 | 2021-08-26 | 이응용 | Functional health food for defecaation inducement and diet |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101896024B1 (en) * | 2017-06-14 | 2018-09-06 | 주식회사 슈퍼내츄럴스 | Functional food compositions comprising extracts of Garcinia Cambogia as active ingredients and method for preparing the same |
| FR3090347B1 (en) * | 2018-12-20 | 2020-12-18 | Oreal | Process for treating keratin fibers using a composition comprising a salt of carnitine or a carnitine derivative comprising an anion of aliphatic dicarboxylic acid |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3023919B2 (en) | 1989-06-14 | 2000-03-21 | ロンザ リミテッド | L-carnitine-magnesium-citrate |
| KR100856241B1 (en) * | 2007-04-25 | 2008-09-03 | 웅진식품주식회사 | A diet food composition using an agar |
| JP5149172B2 (en) * | 2005-07-05 | 2013-02-20 | ロンザ アーゲー | Spray drying method for producing dry carnitine powder or granules |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100109697A (en) * | 2009-04-01 | 2010-10-11 | 주식회사 벤스랩 | Functional composition with the effects of improving hyperlipidemia and reducing body weight |
| KR20110116345A (en) | 2010-04-19 | 2011-10-26 | (주)아모레퍼시픽 | Composition for relieving constipation containing aloe and vegetable oils |
| KR20140057838A (en) | 2012-11-05 | 2014-05-14 | 노길형 | Fermented foods process and production method |
| KR101444875B1 (en) | 2012-12-21 | 2014-09-26 | 주식회사 삼양사 | Beverage composition comprising hibiscus extract and l-carnitine with improved sensory property and stability |
| KR101738912B1 (en) | 2013-11-01 | 2017-05-23 | 이진서 | Composition For Anti-obesity And Diet |
-
2015
- 2015-07-29 KR KR1020150107087A patent/KR101721145B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3023919B2 (en) | 1989-06-14 | 2000-03-21 | ロンザ リミテッド | L-carnitine-magnesium-citrate |
| JP5149172B2 (en) * | 2005-07-05 | 2013-02-20 | ロンザ アーゲー | Spray drying method for producing dry carnitine powder or granules |
| KR100856241B1 (en) * | 2007-04-25 | 2008-09-03 | 웅진식품주식회사 | A diet food composition using an agar |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210104952A (en) | 2020-02-17 | 2021-08-26 | 이응용 | Functional health food for defecaation inducement and diet |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170014179A (en) | 2017-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201692B (en) | ||
| KR101738912B1 (en) | Composition For Anti-obesity And Diet | |
| JP4702745B2 (en) | Mineral absorption promoter and its use | |
| JPH09291039A (en) | Antiobestic medicine comprising procyanidin as active ingredient | |
| CN103918965A (en) | Physical fatigue alleviating beverage | |
| CN106723087A (en) | A kind of tablet containing kelp dietary fiber and preparation method thereof | |
| KR101721145B1 (en) | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement | |
| KR20070113460A (en) | The health food composition for regulating weight | |
| CN114711374A (en) | Composite nutrient powder of ferment fibre and its preparation method | |
| KR100549089B1 (en) | A Health Care Composition for treating or preventing intestinal disease and constipation | |
| JP3462535B2 (en) | Mineral absorption promoting composition | |
| CN107787191B (en) | Composition for weight loss comprising a beverage and beads | |
| JP2008237058A (en) | Dietary supplement | |
| JP2006028051A (en) | Ameliorant for exhausted feeling at time of rising, composition for ameliorating exhausted feeling at time of rising, and food and beverage for ameliorating exhausted feeling at time of rising, containing them | |
| KR100278206B1 (en) | Health supplement composition for growth | |
| KR20190140737A (en) | Vinegar compositions comprising detox-diet material and manufacturing method thereof | |
| KR102314879B1 (en) | Drinking jelly composition comprising Psyllium husk | |
| CN106255502A (en) | Satiety continues agent and makes the lasting method of satiety | |
| JP2008074835A (en) | Harmful metal excretion agent, method of using the same, and food supplement | |
| JPH05238945A (en) | Intestinal environment-improving agent | |
| JP5601747B2 (en) | Composition for internal use for fatigue prevention and preparation for internal use for fatigue prevention | |
| JP2021100421A (en) | Composition for improving liver function, and food composition for improving liver function | |
| KR20040031398A (en) | Diet-food Composition characterized as blocking to absorb carbohydrate and lipid | |
| JP2005263706A (en) | Fat metabolism promotion composition and food and beverage containing the same | |
| CN110710672A (en) | Natural plant active calcium preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| GRNT | Written decision to grant |